亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 人寡肽-20/Human Oligopeptide-20
人寡肽-20/Human Oligopeptide-20
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 10000g起訂1g
品牌 成都云希
外觀 白色粉末
功效 皮膚護理
過期 長期有效
更新 2021-07-05 16:42
 
詳細信息

1.Basic information:

INCI Name: Human Oligopeptide-20 (tissue inhibitor of metalloproteinases-2 (TIMP2))

Reference: PEPHA-TIMP

Formula: C22H38N6O7

Molecular:498.57

Purity: >95%

Source: synthetic

Grade: cosmetic

Odor: no

Stability: stable

Odor: no

MSDS and COA: available for you reference

Solubility: soluble in water

Formulation: available for your reference, please contact us.

Delivery: promptly from stock

Capacity: 350g per month

Appearance: white powder

 

2.Usage: 

anti-aging(restores the dermal tissue and protects and strengthens the collagen)

 

3.Description

Human Oligopeptide-20(TIMP2) is useful in all product applications where

MMP mediated degradation is a concern:

1.innovative anti-aging products for face and body care

2. Sun care and after sun products

3. Protective for UV exposed skin

4. Midterm to long term anti-aging treatments

©2025 成都云希化工有限公司 版權所有   技術支持:化工網   訪問量:41416  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |